Zosano Pharma Corp. (ZSAN) came public near $11 in January 2015 and entered a stairstep decline that initially found support near $2.00 at the start of 2016. That level broke mid-year, dumping to an all-time low at 45-cents in November, ahead of a bounce into 2017. The stock charged higher in February, breaking out above the 200-day EMA, after a migraine relief product candidate produced statistically significant testing results. A pullback to the moving average should reward dip buyers with continued upside that could reach $6.00 to $7.00.
